Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of VUM02 injection added to standard therapy in patients with decompensated cirrhosis
CTR20261256Phase 2Active
- Sponsor
- Wuhan Optics Valley Zhongyuan Pharmaceutical
- Start
- Apr 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of VUM02 in decompensated cirrhosis, sponsored by Wuhan Optics Valley Zhongyuan Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
VUM02
03
Conditions
decompensated cirrhosis
Beyond the preview
Go deeper on CTR20261256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261256.